BPCL has surged 39 per cent in 2024 so far. It traded at Rs 625.60 today against Rs 450.65 at the end of 2023. If one goes by Emkay Global, further re-rating should not be ruled on the OMC counter
BNP prefers Sun Pharma and JB Chemicals in the pharma space and while it likes Apollo Hospitals Enterprise and Metropolis Healthcare Ltd in the healthcare services.
The stock was trading with minor gains at the opening time and hit the day s high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price.
Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined.